Informace o publikaci

Prognostic factors for survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage

Autoři

ROHAN Tomáš MATKULČÍK Peter UHER Michal ČECHOVÁ Barbora STRAKA Matej VÁLEK Vlastimil KLAIL Tomáš ROSINOVÁ Dominika ANDRAŠINA Tomáš

Rok publikování 2022
Druh Konferenční abstrakty
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Popis Purpose: To identify factors affecting survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage (PTD). Materials and Methods: This single-centre retrospective study included 233 consecutive patients undergoing PTD for cancer of biliary origin at a tertiary referral hospital from 1/2005 to 12/2019. Cox regression model was used to assess variables related to overall survival after initial PTD. The variables included demographic (age, sex), imaging (mass forming vs. infiltrative, size of mass forming tumor, localisation, Bismuth-Corlette classification in hilar tumors, presence of metastasis), laboratory (bilirubin, liver enzymes and inflammatory markers before and 3-7 days after the procedure, and hemoglobin, thrombocytes, urea and creatinine before the procedure), and treatment parameters of PTD (number of percutaneous drains, presence and number of implanted metal stents, and performance of endobiliary radiofrequency ablation). Results: In multivariate analysis, age (HR 1.23 per 10 years, p=0.005), location (gallbladder cancer HR 2.82 and p<0.001 compared to hilar cancer; common bile duct cancer HR 0.64 and p=0.049; papilla Vateri HR 0.31 and p=0.002), size of the mass (HR 1.07 per cm, p=0.005), level of bilirubin (?250 umol/L with HR 1.57 and p=0.009) and hemoglobin (?110 g/L with HR 1.93 and p=0.001) were shown to be significant factors affecting survival in patients with cancer of biliary origin since first PTD. Conslusion: Age, tumour location, mass size, bilirubin and hemoglobin levels before the first PTD have been shown to be significant prognostic factors for survival in patients with cancer of biliary origin treated with PTD.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info